Skip to content
2000
Volume 19, Issue 3
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

DNA interstrand cross-linking (ICL) agents are an important group of cytotoxic drugs with the capability of binding covalently between two strands of DNA, thereby preventing vital processes such as replication or transcription in dividing cells. In anticancer therapy however, their potential is limited due to the resistance by various mechanisms. In order to develop highly effective antitumor drugs it is necessary to study both effective ICL formations and their subsequent repair mechanisms. This review presents an overview of development over the past decade and the use of both well-known and new DNA interstrand cross-linking agents. Their potential in applications especially as anticancer chemotherapeutics in the framework of current knowledge of repair mechanisms and development of combined chemotherapy is discussed

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986712803414295
2012-01-01
2025-05-03
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986712803414295
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test